Public-private partnership: From there to here

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 99, Issue SUPPL. 1, 2005, Pages 9-14

  Croft, Simon L ^a  

^a Drugs for Neglected Diseases Initiative   (Switzerland)

Author keywords

Drugs for Neglected Diseases Initiative; Institute for OneWorld Health; Medicines for Malaria Venture; Public private partnership for product development; TB Alliance; Translational research

Indexed keywords

AMODIAQUINE; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ARTESUNATE; CHLORPROGUANIL PLUS DAPSONE; EFLORNITHINE; IMIDAZOLE DERIVATIVE; MACROLIDE; MEFLOQUINE; MILTEFOSINE; NEW DRUG; NIFURTIMOX; PAROMOMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT;

ARTICLE; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG RESEARCH; ENDEMIC DISEASE; FINANCE; HEALTH CARE DELIVERY; HUMAN; ORGANIZATION; SOCIAL WELFARE; TROPICAL DISEASE;

EID: 23844529465     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2005.06.008     Document Type: Article

References (14)

1. T.T. Ashburn K.B. Thor Drug repositioning: Identifying and developing new uses for existing drugs Nature Rev. Drug Discov. 3 2004 673-683
2. Food and Drugs Administration, 2004. Innovation or Stagnation? Challenge and Opportunity on the Critical Pathway to New Medical Products. Department of Health and Human Services, Washington, D.C. www.fda.gov/oc/ initiatives/criticalpath/whitepaper.html [accessed October 2004].
3. Janssens, P.G., Kivits, M., Vuylsteke, J., 1992. Médecine et hygiène en Afrique centrale de 1885 à nos jours. Brussels, Fondation Roi Baudoin.
4. S. Nwaka R. Ridley Virtual drug discovery and development for neglected diseases through public-private partnerships Nature Rev. Drug Discov. 2 2003 919-928
5. S. Omura Philosophy of new drug discovery Microbiol. Rev. 50 1986 259-279
6. B. Pécoul P. Chirac P. Trouiller J. Pinel Access to essential drugs in poor countries: A lost battle? JAMA 281 1999 361-367
7. M. Reich Public-private partnerships for public health Nature Med. 6 2000 617-620
8. S. Sundar Indian Kala-azar - better tools needed for diagnosis and treatment J. Postgrad. Med. 49 2003 29-30
9. D. Taylor The pharmaceutical industry and health in the third world Soc. Sci. Med. 22 1986 1141-1149
10. P. Trouiller P. Olliaro Drug development output from 1975 to 1996: What proportion for tropical diseases? Int. J. Infect. Dis. 3 1999 61-63
11. P. Trouiller P. Olliaro E. Torreele J. Orbinski R. Laing N. Ford Drug development for neglected diseases: A deficient market and a public-health policy failure Lancet 359 2002 2188-2194
12. J. Vane W. Gutteridge TDR and the drug industry World Health (May) 1985 21-23
13. J.L. Vennestrom S. Arbe-Barnes R. Brun S.A. Charman F.C.K. Chiu J. Chollet Y. Dong A. Dorn D. Hunziker H. Matile K. McIntosh M. Padmanilayam J.S. Tomas C. Scheurer B. Scorneaux Y. Tang H. Urwyler S. Wittlin W. Charman Identification of an antimalarial synthetic trioxalane drug development candidate Nature 430 2004 900-904
14. N.J. White Antimalarial drug resistance J. Clin. Invest. 113 2004 1084-1092